Recent news on Teveten

Biovail Reports Record Fourth Quarter, Year-End 2006 Financial Results  -  Mar 15, 2007
CNW Telbec (Communiqués de presse),Further to the May 2005 sale to Kos, Biovail no longer has an ongoing financial interest in Teveten and Teveten HCT. However, in 2006, the Company increased

Research and Markets: Fenofibrate is Solvay Pharmaceuticals ...  -  Jan 12, 2007
PharmaLive.com (press release),Marinol (dronabinol) and Serc (betahistine); the influenza vaccine, Influvac; the pancreatic enzyme, Creon; and Teveten (eprosartan mesylate) for

Kos Reports a 17% Increase in Revenue, Earnings Per Share of $0.71 ...  09 Nov 2006
Third quarter 2006 revenues for Kos' hypertension portfolio, comprised of Teveten(R), Teveten(R) HCT and Cardizem(R) LA totaled $35.7 million. ... -Genetic Engineering News (press release), Biovail Reports Third-Quarter 2006 Financial Results  09 Nov 2006
...launch of Ultram(R) ER; partially offset by declines in Biovail Pharmaceuticals Canada (BPC) and the Company's generic products, and the sale of Teveten to Kos ... -Canada NewsWire (press release), Kos to Report Third Quarter Results on November 9, 2006 Conference ...  Nov 3, 2006
...activities. The Company currently markets Niaspan ® , Advicor ® , Azmacort ® , Cardizem ® LA, Teveten ® and Teveten ® HCT. -Business Wire (press release), PolyMedix Appoints Vice President of Clinical Development  Nov 8, 2006
...has worked on the development of such major pharmaceutical products as Lupron, Pravachol, Capoten, Kerlone, Cardene, Calan, Avandia, Actos, Teveten, and Atacand ... -PharmaLive.com (press release), Kos to Report Third Quarter Results on November 9, 2006 Conference ...  Nov 3, 2006
...development activities. The Company currently markets Niaspan(R), Advicor(R), Azmacort(R), Cardizem(R)LA, Teveten(R) and Teveten(R)HCT. -PharmaLive.com (press release), Foro de Shell Security - Seguridad informática  Oct 26, 2006
The incidence was accurately determ tetracycline ned to be 4 cases per million population in Bangkok teveten but may be closer to 6 cases per million populati ... -Shell Security, Kos Pharmaceuticals Announces Compliance with NASDAQ Continued ...  Sep 18, 2006
...development activities. The Company currently markets Niaspan(R), Advicor(R), Azmacort(R), Cardizem(R)LA, Teveten(R) and Teveten(R)HCT. -Genetic Engineering News

Kos to Present at the UBS Global Life Sciences Conference  Sep 19, 2006
The Company currently markets Niaspan(R), Advicor(R), Azmacort(R), Cardizem(R)LA, Teveten(R) and Teveten(R)HCT. Contact Kos Pharmaceuticals, Inc. ... -PharmaLive.com

Kos Announces Positive Overall Results for Two Phase III Trials of ...  Sep 21, 2006
...activities. The Company currently markets Niaspan(R), Advicor(R), Azmacort(R), Cardizem(R)LA, Teveten(R) and Teveten(R)HCT. Kos ... -Genetic Engineering News

Kos Reports 25% Increase in Revenue, Solid Financial Results and ...  Aug 8, 2006
Second quarter 2006 revenues for Kos' hypertension portfolio, comprised of Teveten(R), Teveten(R) HCT and Cardizem(R) LA totaled $31.3 million. ... -Business Wire

Biovail Reports Second-Quarter 2006 Financial Results; Company ...  Aug 10, 2006
...were impacted by the restructuring of Biovail's US commercial operations, a write-down of assets primarily associated with the sale of Teveten and Teveten HCT ... -Genetic Engineering News

Drugmaker Biovail's second-quarter profit soars to US$80.6 million  Aug 10, 2006
...were also hurt by the restructuring of Biovail's US commercial operations, a writedown of assets primarily associated with the sale of Teveten and Teveten HCT ... -CBC News

Arisaph Pharmaceuticals Announces Second Closing of $8 Million ...  Aug 9, 2006
...activities. The Company currently markets Niaspan(R), Advicor(R), Azmacort(R), Cardizem(R)LA, Teveten(R), and Teveten(R)HCT. Kos ... -PR Newswire

Kos to Report Second Quarter Results on August 8, 2006 Conference ...  Jul 27, 2006
...activities. The Company currently markets Niaspan(R), Advicor(R), Azmacort(R), Cardizem(R)LA, Teveten(R) and Teveten(R)HCT. Kos ... -Genetic Engineering News

Drugmaker Biovail's second-quarter profit soars to US$80.6 million  Aug 10, 2006
Pharmaceuticals, Inc., and a $4.9-million writeoff of Cardizem LA and Teveten inventories not purchased by Kos. Those items totalled $50.1 million. ... -CBC News

Manhattan Research Reveals Top Pharmaceutical Websites Visited by ...  Aug 2, 2006
Patanol, Viread, Keppra, Lupron, Oxytrol, Symlin, Byetta, Avonex, Reyataz, Kaletra, Neulasta, Zelnorm, Nuva Ring, Prevacid, Androgel, Teveten, Rebif and Avapro ... -Yahoo! News

Kos Submits Supplemental New Drug Application To FDA For New ...  Jul 12, 2006
...the treatment of cholesterol disorders, Azmacort(R) forthe treatment of asthma, Cardizem(R) LA for the treatment ofhypertension and angina, and Teveten(R) and ... -Finanzen.net

Kos Submits Supplemental New Drug Application To FDA For New ...  Jul 13, 2006
...treatment of cholesterol disorders, Azmacort(R) for the treatment of asthma, Cardizem(R) LA for the treatment of hypertension and angina, and Teveten(R) and ... -PipelineReview.com



Kos Reports Continued Double Digit Increase in Revenue, Financial ...  May 9, 2006
Revenues for Kos' hypertension portfolio, comprised of Teveten(R),Teveten HCT and Cardizem(R)LA, totaled $31.6 million, excluding a $1.6million reduction in ... - Finanzen.net

Kos Pharma Slips To Loss In Q1 On Costs; To Buy Back Up To 7 ...  May 9, 2006
The hypertension portfolio, comprising Teveten, Teveten HCT and CardizemLA, totaled $31.6 million, excluding a $1.6 million reduction in wholesaler inventories ... - Trading Markets

Biovail Reports First-Quarter 2006 Financial Results; Company ...  May 11, 2006
Inc. (Kos), which included the divestiture of the Teveten line of products. ... 2005. Biovail no longer has an economic interest in Teveten. ... - Genetic Engineering News

Biovail Q1 Earnings Surge On Strong Sales Of Antidepressant ...  May 11, 2006
...(KOS | charts | news | PowerRating), which included the divestiture of the Teveten line of products. ... Biovail no longer has an economic interest in Teveten. ... - Trading Markets

CORRECTING and REPLACING Kos Announces Presentation at the Bank of ...  May 5, 2006
...the treatment of cholesterol disorders, Azmacort(R) forthe treatment of asthma, Cardizem(R)LA for the treatment ofhypertension and angina, and Teveten(R) and ... - Finanzen.net

Kos and SkyePharma Sign Exclusive License Agreement for the ...  May 7, 2006
...for the treatment of cholesterol disorders, Azmacort forthe treatment of asthma, Cardizem(R)LA for the treatment ofhypertension and angina, and Teveten(R) and ... - Finanzen.net

SkyePharma and Kos Announce Exclusive Licence Agreement for ...  May 7, 2006
...treatment of cholesterol disorders, Azmacort for the treatment of asthma, Cardizem® LA for the treatment of hypertension and angina, and Teveten® and Teveten ... - Yahoo! News

Kos and SkyePharma Sign Exclusive License Agreement for the ...  May 7, 2006
...the treatment of cholesterol disorders, Azmacort for the treatment of asthma, Cardizem(R)LA for the treatment of hypertension and angina, and Teveten(R) and ... - Business Wire





Biovail Reports Fourth Quarter, Year-End 2005 Financial Results  Mar 23, 2006
Cardizem(R) LA; partially offset by declines in Biovail Pharmaceuticals Canada (BPC) and Biovail's generics portfolio, as well as in Teveten revenues following ... - Business Wire

Biovail Reports Fourth Quarter, Year-End 2005 Financial Results  Mar 23, 2006
Cardizem ® LA; partially offset by declines in Biovail Pharmaceuticals Canada (BPC) and Biovail's generics portfolio, as well as in Teveten revenues following ... - CCNMatthews



Kos Reports 2005 Fourth Quarter and Full Year Results, Forecasts ...  Feb 23, 2006
Total prescriptions for Cardizem(R)LA increased 19% in 2005 versus growth in the calcium channel blocker market of only 1%, and the Teveten(R) franchise ... - PharmaLive.com,

Kos Announces Presentation at the Deutsche Bank Small Cap Growth ...  Feb 6, 2006
...the treatment of cholesterol disorders, Azmacort(R) for the treatment of asthma, Cardizem(R)LA for the treatment of hypertension and angina, and Teveten(R) and ... - PharmaLive.com

Lane, Earl & Cox Advertising Success at Global Awards  Jan 13, 2006
UXBRIDGE, England, Jan. 13, 2006-The Hedge press advertisement for Solvay’s Teveten notched up its second international award at the end of 2005. ... - PharmaLive.com

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional